Medical Director of Specialty Services, Southwest CARE Center
Infectious Disease
Dr. Joel E. Gallant, MD
|
|
Give Review
Joel E. Gallant, MD is an expert in the field of Infectious Disease. He went to medical school at University of California San Francisco School of Medicine. University of California San Francisco School of Medicine is one of the top medical schools in the US. University of California San Francisco School of Medicine is ranked 3 in research and 3 in primary care medicine He received 2 awards: "Super Doctor" and "HIV Clinical Educator Award". Joel Gallant is a published physician as well. He has 88 publications published. The latest was: HIV drug resistance in adults failing early antiretroviral treatment: results from the HIV Prevention Trials Network 052 trial. He is registered with Medicare and accepts Medicare payments.
Publications
- HIV drug resistance in adults failing early antiretroviral treatment: results from the HIV Prevention Trials Network 052 trial.
- Rationale and Evidence for Human Immunodeficiency Virus Treatment as Prevention at the Individual and Population Levels.
- Antiretroviral Treatment of Adult HIV Infection: 2014 Recommendations of the International Antiviral Society-USA Panel.
- Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled...
- A randomized, double-blind comparison of single tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single tablet regimen efavirenz/emtricitabine/...
- Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1-Infected Patients: Week ...
- Nephrotoxicity of Antiretroviral Agents: Is the List Getting Longer?
- Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda.
- Essential components of effective HIV care: a policy paper of the HIV Medicine Association of the Infectious Diseases Society of America and the Ryan White Medical Pro...
- A Systematic Review of HIV/AIDS Survival and Delayed Diagnosis Among Hispanics in the United States.
- Association between Use of HMG CoA Reductase Inhibitors and Mortality in HIV-Infected Patients.
- Human immunodeficiency virus infection and hospital mortality in acute lung injury patients.
- A case of seronegative HIV-1 infection.
- What does the generalist need to know about HIV infection?
- Routine HIV screening, Part 2: beyond testing and referral.
- CROI 2009: a few key presentations on antiretroviral therapy.
- Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection.
- Preaching to the choir: advocating routine HIV testing.
- When to start antiretroviral therapy? NA-ACCORD stimulates the debate.
- HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
- The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.
- Antiretroviral rounds. Is that "one pill" treatment enough?
- When to start antiretroviral therapy: a swinging pendulum?
- Initial regimens for the treatment-naive patient: current understanding and practice.
- Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
- Making sense of blips.
- Should antiretroviral therapy be started earlier?
- When and how to use tipranavir and darunavir.
- Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
- Approach to the treatment-experienced patient.
- Report from Los Angeles: the 14th Conference on Retroviruses and Opportunistic Infections (CROI). Management of treatment-naïve patients.
- Renal safety of tenofovir disoproxil fumarate.
- Drug resistance after failure of initial antiretroviral therapy in resource-limited countries.
- Antiretroviral update from the 46th ICAAC.
- Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunolo...
- The M184V mutation: what it does, how to prevent it, and what to do with it when it's there.
- Editorial comment: predictors of response--updating the traditional list.
- HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients.
- Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circ...
- Editorial comment: treating the experienced patient--when and how to use new agents.
- High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection.
- Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring.
- Antiretroviral news from the 10th EACS, Dublin.
- Antiretroviral news from the 45th ICAAC.
- False positive viral load results: recent problems and solutions.
- Psychological distress and physical pain appear to have no short-term adverse impact on plasma HIV-1 RNA levels in patients on successful HAART.
- 3rd IAS conference: initial therapy, switching, and new strategies.
- Antiretroviral rounds. Virologic failure: true or false?
- Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
- Treatment of naïve patients: update from the 12th CROI.
- Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
- Antiretroviral therapy update from the 44th ICAAC.
- Editorial comment: strategies for success--a return to "hit early"?
- XV International AIDS Conference in Bangkok: antiretroviral therapy.
- The choice of the nucleoside backbone in initial therapy.
- Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy.
- The ideal nucleoside/nucleotide backbone.
- Current perspectives on the nucleoside/nucleotide components of combination antiretroviral therapy.
- Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection.
- HIV infection--how to lower your risk.
- HIV counseling, testing, and referral.
- Editorial comment: thoughts on the once-daily-dosing bandwagon.
- High-risk behavior and potential transmission of drug-resistant HIV among injection drug users.
- Early treatment of HIV.
- Report from San Francisco: The 11th Conference on Retroviruses and Opportunistic Infections (CROI). Antiretroviral therapy: the naïve patient.
- Report from San Francisco: The 11th Conference on Retroviruses and Opportunistic Infections (CROI). The tenacity of NNRTI drug resistance.
- Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy.
- Antiretroviral news from the Chicago: the 43rd ICAAC.
- Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.
- Tenofovir disoproxil fumarate.
- Antiretroviral therapy update from the 2nd IAS Conference.
- AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.
- The optimal use of enfuvirtide.
- Report from Boston: the 10th Conference on Retroviruses and Opportunistic Infections (CROI).
- Current management challenges in HIV: antiretroviral resistance.
- Drug resistance and treatment of experienced patients.
- Current status of antiretroviral treatment interruption and intermittent therapy strategies.
- Report from ICAAC: new drugs and antiretroviral therapy for naïve patients.
- Drug resistance and the treatment of experienced patients.
- Loss of HIV-1-specific immunity during treatment interruption in 2 chronically infected patients.
- Selected topics from the 9th Conference on Retroviruses and Opportunistic Infections.
- The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
- New drugs in clinical development and treatment of naive patients.
- Antiretroviral news from the 41st ICAAC.
- Hepatitis C Virus Testing in Adults Living with HIV: A Need for Improved Screening Efforts.
- Antiretroviral drug resistance and resistance testing.
- Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-Naïve HIV-1 patients: meta-analysis of randomized clinical studies.
Schools
University Of California San Francisco School Of Medicine
Yale New Haven Hospital
Johns Hopkins Hospital
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- Super Doctor
- HIV Clinical Educator Award
Education
-
Johns Hopkins School of Hygiene and Public Health -
Yale-New Haven Hospital -
University of California San Francisco School of Medicine
Drug Facts
| NPI NUMBER | 1578501243 | |
| NPPES Provider LastName | GALLANT | |
| NPPES Provider FirstName | JOEL | |
| NPPES Provider ZIPCode | 875054765 | |
| NPPES Provider State | NM | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 1585.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 14.0 | |
| Percent Opioid Claims | 0.88 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1578501243 |
| Last Name Of The Provider | GALLANT |
| First Name Of The Provider | JOEL |
| View All |
Similar Doctors
|
|
Dr. Melissa L. Fox, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kerry Dierberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul G. Auwaerter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher J. Hoffmann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John Aucott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie B. Trivedi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel N. Blankson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kieren A. Marr, MD
This Doctor is OpenDoctor Recommended.
|